Bromodomains as therapeutic targets in cancer

Briefings in Functional Genomics

Volumn 12, Issue 3, 2013, Pages 219-230

  Barbieri, Isaia ^a   Cannizzaro, Ester ^a,b   Dawson, Mark A ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

BRD4; Bromodomain; Cancer; Epigenetics

Indexed keywords

BRD2 PROTEIN; BRD3 PROTEIN; BRD4 PROTEIN; CYCLIC AMP; DNA; HISTONE; HISTONE ACETYLTRANSFERASE PCAF; MYC PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; BROMODOMAIN; CANCER GENETICS; CHROMATIN ASSEMBLY AND DISASSEMBLY; COMPLEX FORMATION; CRYSTAL STRUCTURE; DNA HISTONE INTERACTION; EPIGENETICS; GENE EXPRESSION; HISTONE ACETYLATION; HISTONE METHYLATION; NUCLEOSOME; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN STRUCTURE;

BRD4; BROMODOMAIN; CANCER; EPIGENETICS;

EPIGENOMICS; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN STRUCTURE, TERTIARY; TRANSCRIPTION FACTORS;

EID: 84878450298     PISSN: 20412649     EISSN: 20412657     Source Type: Journal    
DOI: 10.1093/bfgp/elt007     Document Type: Article

References (91)

1. Dawson MA, Kouzarides T, Huntly BJ. Targeting epigenetic readers in cancer. NEnglJMed 2012;367:647-57.
2. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012;150:12-27.
3. You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 2012;22:9-20.
4. Sandoval J, Esteller M. Cancer epigenomics: beyond genomics. Curr Opin Genet Dev 2012;22:50-5.
5. Shih AH, Abdel-Wahab O, Patel JP, et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012;12:599-612.
6. Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol Oncol 2012;6:579-89.
7. Johnstone R. Histone deacetylase inhibitors in cancer therapyIs transcription the primary target?. Cancer Cell 2003;4:13-8.
8. Prince HM, Dickinson M. Romidepsin for cutaneous T-cell lymphoma. Clin Cancer Res 2012;18:3509-15.
9. Munster PN, Thurn KT, Thomas S, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. BrJCancer 2011;104:1828-35.
10. Yong WP, Goh BC, Soo RA, et al. Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies. Ann Oncol 2011;22:2516-22.
11. Huang B, Yang XD, Zhou MM, et al. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol Cell Biol 2009;29:1375-87.
12. Lamonica JM, Deng W, Kadauke S, et al. Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes. ProcNatl Acad SciUSA 2011;108:E159-168.
13. Mujtaba S, Zeng L, Zhou MM. Structure and acetyl-lysine recognition of the bromodomain. Oncogene 2007;26: 5521-7.
14. Dhalluin C, Carlson JE, Zeng L, et al. Structure and ligand of a histone acetyltransferase bromodomain. Nature 1999; 399:491-6.
15. Prinjha RK, Witherington J, Lee K. Place your BETs: the therapeutic potential of bromodomains. Trends Pharmacol Sci 2012;33:146-53.
16. Filippakopoulos P, Knapp S. The bromodomain interaction module. FEBS Lett 2012;586:2692-704.
17. Dawson MA, Prinjha RK, Dittmann A, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011;478:529-33.
18. Liu J, Lee W, Jiang Z, et al. Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. GenomeRes 2012.
19. Ciro M, Prosperini E, Quarto M, et al. ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res 2009;69:8491-8.
20. Hennig EE, Mikula M, Rubel T, etal. Comparative kinome analysis to identify putative colon tumor biomarkers. JMol Med (Berl) 2012;90:447-56.
21. Zhou Y, Schmitz KM, Mayer C, et al. Reversible acetylation of the chromatin remodelling complex NoRC is required for non-coding RNA-dependent silencing. Nat Cell Biol 2009;11:1010-6.
22. Jones MH, Hamana N, Nezu J, et al. A novel family of bromodomain genes. Genomics 2000;63:40-5.
23. Nebral K, Denk D, Attarbaschi A, et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 2009;23:134-43.
24. LeRoy G, Rickards B, Flint SJ. The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription. Mol Cell 2008;30:51-60.
25. Lenburg ME, Sinha A, Faller DV, et al. Tumor-specific and proliferation-specific gene expression typifies murine transgenic B cell lymphomagenesis. J Biol Chem 2007;282: 4803-11.
26. French CA, Ramirez CL, Kolmakova J, et al. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene 2008;27:2237-42.
27. Thompson-Wicking K, Francis RW, Stirnweiss A, et al. Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma. Oncogene 2012.
28. Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature 2010;468:1067-73.
29. Mantovani F, Drost J, Voorhoeve PM, etal. Gene regulation and tumor suppression by the bromodomain-containing protein BRD7. Cell Cycle 2010;9:2777-81.
30. Yamada HY, Rao CV. BRD8 is a potential chemosensitizing target for spindle poisons in colorectal cancer therapy. IntJ Oncol 2009;35:1101-9.
31. Grunwald C, Koslowski M, Arsiray T, et al. Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer. IntJCancer 2006;118:2522-8.
32. Laue K, Daujat S, Crump JG, et al. The multidomain protein Brpf1 binds histones and is required for Hox gene expression and segmental identity. Development 2008;135: 1935-46.
33. Kalla C, Nentwich H, Schlotter M, et al. Translocation t(X;11)(q13;q23) in B-cell chronic lymphocytic leukemia disrupts two novel genes. Genes Chromosomes Cancer 2005; 42:128-43.
34. Banting GS, Barak O, Ames TM, et al. CECR2, a protein involved in neurulation, forms a novel chromatin remodeling complex with SNF2L. HumMol Genet 2005;14:513-24.
35. Chung YR, Schatoff E, Abdel-Wahab O. Epigenetic alterations in hematopoietic malignancies. IntJHematol 2012;96: 413-27.
36. Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011;471:189-95.
37. Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene 2004;23:4225-31.
38. Jiang J, Lu J, Lu D, et al. Investigation of the acetylation mechanism by GCN5 histone acetyltransferase. PLoS One 2012;7:e36660.
39. Leachman NT, Brellier F, Ferralli J, et al. ATAD2B is a phylogenetically conserved nuclear protein expressed during neuronal differentiation and tumorigenesis. Dev Growth Differ 2010;52:747-55.
40. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007;7:823-33.
41. Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011;469:539-42.
42. Farhang-Fallah J, Yin X, Trentin G, et al. Cloning and characterization of PHIP, a novel insulin receptor substrate-1 pleckstrin homology domain interacting protein. J Biol Chem 2000;275:40492-7.
43. Endo M, Yasui K, Zen Y, etal. Alterations of the SWI/SNF chromatin remodelling subunit-BRG1 and BRM in hepatocellular carcinoma. Liver Int 2012.
44. Schneppenheim R, Fruhwald MC, Gesk S, et al. Germline nonsense mutation and somatic inactivation of SMARCA4/ BRG1 in a family with rhabdoid tumor predisposition syndrome. AmJHum Genet 2010;86:279-84.
45. Wong AK, Shanahan F, Chen Y, et al. BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res 2000;60:6171-7.
46. Wilson BG, Roberts CWM. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011;11:481-92.
47. Li W, Shang C, Guan C, et al. Low expression of Sp100 in laryngeal cancer: correlation with cell differentiation. Med SciMonit 2010;16:BR174-178.
48. Pryor JG, Brown-Kipphut BA, Iqbal A, et al. Microarray comparative genomic hybridization detection of copy number changes in desmoplastic melanoma and malignant peripheral nerve sheath tumor. AmJDermatopathol 2011;33: 780-5.
49. Sille FC, Thomas R, Smith MT, et al. Post-GWAS functional characterization of susceptibility variants for chronic lymphocytic leukemia. PLoS One 2012;7:e29632.
50. Wang PJ, Page DC. Functional substitution for TAF(II)250 by a retroposed homolog that is expressed in human spermatogenesis. HumMol Genet 2002;11:2341-6.
51. Klugbauer S, Rabes HM. The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas. Oncogene 1999;18:4388-93.
52. Friedman JR, Fredericks WJ, Jensen DE, et al. KAP-1, a novel corepressor for the highly conserved KRAB repression domain. Genes Dev 1996;10:2067-78.
53. Khetchoumian K, Teletin M, Mark M, et al. TIF1delta, a novel HP1-interacting member of the transcriptional intermediary factor 1 (TIF1) family expressed by elongating spermatids. J Biol Chem 2004;279:48329-41.
54. Huang H, Rambaldi I, Daniels E, et al. Expression of the Wdr9 gene and protein products during mouse development. DevDyn 2003;227:608-14.
55. Bierkens M, Krijgsman O, Wilting SM, et al. Focal aberrations indicate EYA2 and hsa-miR-375 as oncogene and tumor suppressor in cervical carcinogenesis. Genes Chromosomes Cancer 2012.
56. Masselink H, Bernards R. The adenovirus E1A binding protein BS69 is a corepressor of transcription through recruitment of N-CoR. Oncogene 2000;19:1538-46.
57. Chung CW, Dean AW, Woolven JM, etal. Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery. JMedChem 2012;55(2):576-86.
58. Zeng L, Li J, Muller M, et al. Selective small molecules blocking HIV-1 Tat and coactivator PCAF association. JAmChemSoc 2005;127:2376-7.
59. Sachchidanand, Resnick-Silverman L, Yan S, et al. Target structure-based discovery of small molecules that block human p53 and CREB binding protein association. Chem Biol 2006;13:81-90.
60. Nicodeme E, Jeffrey KL, Schaefer U, et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010; 468:1119-23.
61. French CA, Miyoshi I, Kubonishi I, et al. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res 2003;63:304-7.
62. You J, Croyle JL, Nishimura A, et al. Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell 2004;117: 349-60.
63. Muntean AG, Tan J, Sitwala K, et al. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell 2010;17: 609-21.
64. Lin C, Smith ER, Takahashi H, et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell 2010;37: 429-37.
65. Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011;478:524-8.
66. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146(6):904-17.
67. Mertz JA, Conery AR, Bryant BM, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 2011;108: 16669-74.
68. Belloni E, Trubia M, Gasparini P, et al. 8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes. GenesChromosomes Cancer 2005;42:320-5.
69. Le Douarin B, Zechel C, Garnier JM, et al. The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBOJ 1995;14:2020-33.
70. Chambon M, Orsetti B, Berthe ML, et al. Prognostic significance of TRIM24/TIF-1alpha gene expression in breast cancer. AmJ Pathol 2011;178:1461-9.
71. Allton K, Jain AK, Herz HM, et al. Trim24 targets endogenous p53 for degradation. Proc Natl Acad Sci US A 2009; 106:11612-6.
72. Morsut L, Yan KP, Enzo E, et al. Negative control of Smad activity by ectodermin/Tif1gamma patterns the mammalian embryo. Development 2010;137:2571-8.
73. Tsai WW, Wang Z, Yiu TT, et al. TRIM24 links a non-canonical histone signature to breast cancer. Nature 2010;468:927-32.
74. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011;11:481-92.
75. Reisman DN, Sciarrotta J, Wang W, et al. Loss of BRG1/ BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res 2003; 63:560-6.
76. Medina PP, Romero OA, Kohno T, et al. Frequent BRG1/ SMARCA4-inactivating mutations in human lung cancer cell lines. HumMutat 2008;29:617-22.
77. Glaros S, Cirrincione GM, Palanca A, etal. Targeted knockout of BRG1 potentiates lung cancer development. Cancer Res 2008;68:3689-96.
78. Bultman SJ, Herschkowitz JI, Godfrey V, et al. Characterization of mammary tumors from Brg1 heterozygous mice. Oncogene 2008;27:460-8.
79. Bannister AJ, Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature 1996;384(6610):641-3.
80. Munshi N, Merika M, Yie J, et al. Acetylation of HMG I(Y) by CBP turns off IFN beta expression by disrupting the enhanceosome. Mol Cell 1998;2:457-67.
81. Merika M, Williams AJ, Chen G, et al. Recruitment of CBP/p300 by the IFN beta enhanceosome is required for synergistic activation of transcription. Mol Cell 1998;1: 277-87.
82. Mujtaba S, He Y, Zeng L, etal. Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol Cell 2004;13:251-63.
83. Lai JL, Jouet JP, Bauters F, et al. Chronic myelogenous leukemia with translocation (8;22): report of a new case. Cancer GenetCytogenet 1985;17:365-6.
84. Borrow J, Stanton VP, Jr, Andresen JM, et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 1996;14:33-41.
85. Chaffanet M, Gressin L, Preudhomme C, et al. MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). Genes Chromosomes Cancer 2000;28:138-44.
86. Heemers HV, Debes JD, Tindall DJ. The role of the transcriptional coactivator p300 in prostate cancer progression. Adv ExpMed Biol 2008;617:535-40.
87. Bouchal J, Santer FR, Hoschele PP, et al. Transcriptional coactivators p300 and CBP stimulate estrogen receptor-beta signaling and regulate cellular events in prostate cancer. Prostate 2011;71:431-7.
88. Debes JD, Schmidt LJ, Huang H, et al. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 2002;62:5632-6.
89. Santer FR, Hoschele PP, Oh SJ, et al. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther 2011;10: 1644-55.
90. Matzuk MM, McKeown MR, Filippakopoulos P, et al. Small-molecule inhibition of BRDT for male contraception. Cell 2012;150(4):673-84.
91. Gaucher J, Boussouar F, Montellier E, et al. Bromodomain-dependent stage-specific male genome programming by Brdt. EMBOJ 2012;31:3809-20.